Evidence map›Paper›PMID 38523699›Full record

ArticleEuropean journal of medicinal chemistry2023

Lipidation and PEGylation Strategies to Prolong the

Maricel Gomez-Soler, Erika J Olson, Elena Rubio de la Torre, Chunxia Zhao, Ilaria Lamberto, Dillon T Flood, Waleed Danho, Bernhard C Lechtenberg, Stefan J Riedl, Philip E Dawson and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Maricel Gomez-SolerCancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
Erika J OlsonDepartments of Chemistry and Cell and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, United States.
Elena Rubio de la TorreCancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
Chunxia ZhaoCancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
Ilaria LambertoCancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
Dillon T FloodDepartments of Chemistry and Cell and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, United States.
Waleed DanhoDel Mar, California 92014, United States.
Bernhard C LechtenbergCancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
Stefan J RiedlCancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
Philip E DawsonDepartments of Chemistry and Cell and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, United States.
Elena B PasqualeCancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
Sanford Burnham Prebys Medical Discovery Institute · USScripps Research Institute · USUniversidad del Mar · CL

Funding

Discovery of Selective Inhibitors for the EphA4 KinaseR01AG062617 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE, Eduard A. Sergienko · 2022 to 2023
$1.5M
NIA NIH HHS R01 AG062617NINDS NIH HHS R01 NS087070
6 · The paper itself

Abstract

The EphA4 receptor tyrosine kinase plays a role in neurodegenerative diseases, inhibition of nerve regeneration, cancer progression and other diseases. Therefore, EphA4 inhibition has potential therapeutic value. Selective EphA4 kinase inhibitors are not available, but we identified peptide antagonists that inhibit ephrin ligand binding to EphA4 with high specificity. One of these peptides is the cyclic

Indexed as

Ephrin-A5Receptor, EphA4AnimalsHalf-LifeLigandsMicePolyethylene GlycolsEphrin-A5LigandsPolyethylene GlycolsReceptor, EphA4cancerEph receptorephrinnerve injuryneurodegenerationpeptide antagonist

Identifiers

PMID38523699
PMCPMC10959496
OpenAlexW4387675619

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.